59430-62-5

Basic information

• Product Name: 4-aminohydratropic acid
• Synonyms: 4-aminohydratropic acid
• CAS NO: 59430-62-5
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 165.18914
• EINECS: 261-758-8
• Mol File: 59430-62-5.mol
• Article Data: 15

Chemical Properties

• Melting Point: 132-134°
• Boiling Point: 345°C at 760 mmHg
• Flash Point: 162.4°C
• Appearance: /
• Density: 1.210±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 2.41E-05mmHg at 25°C
• Refractive Index: 1.593
• Storage Temp.: 2-8°C
• PKA: 4.01±0.10(Predicted)
• CAS DataBase Reference: 4-aminohydratropic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-aminohydratropic acid(59430-62-5)
• EPA Substance Registry System: 4-aminohydratropic acid(59430-62-5)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 59430-62-5(Hazardous Substances Data)

Usage

General Description

4-Aminohydratropic acid is a chemical compound with the molecular formula C9H11NO3. It is a derivative of tropic acid and contains an amino group. 4-aminohydratropic acid is used as a precursor in the synthesis of pharmaceuticals and other organic compounds. It has been studied for its potential in medicinal chemistry and drug development, particularly in the field of central nervous system disorders. 4-Aminohydratropic acid is also used as a building block in organic synthesis and chemical research. Its structure and properties make it a valuable tool in the development of new drugs and chemicals.

InChI:InChI=1/C9H11NO2/c1-6(9(11)12)7-2-4-8(10)5-3-7/h2-6H,10H2,1H3,(H,11,12)

Upstream product

• 39718-97-3 methyl 2-(4-aminophenyl)propanoate 
• 50415-69-5 methyl 2-(4-nitrobenzene)propionate 
• 139223-62-4 3-(4-aminophenyl)-acrylic acid hydrochloride 
• 65784-32-9 3-Nitro-4-hydroxyphenyl-α-methylacetic acid 
• 64-17-5 ethanol 
• 19910-33-9 2-(4-nitrophenyl)propanoic acid 
• 7440-05-3 palladium 
• 492-37-5 hydratropic acid 
• 106-40-1 4-bromo-aniline 
• 83756-25-6 2-<4-(2,5-dimethylpyrrol-1-yl)benzilidene>-1,3-dithian 
• 95337-70-5 4-(2,5-dimethylpyrrol-1-yl)benzaldehyde 
• 26165-63-9 2-<4-(2,5-dimethylpyrrol-1-yl)phenyl>ethanoic acid 
• 5044-24-6 1-(4-Bromo-phenyl)-2,5-dimethyl-1H-pyrrole 
• 117551-07-2 (4-Amino-phenyl)-acetyl chloride 

Downstream Products

• 32868-25-0 2-(4-amminofenil)propionico d'etile 
• 110728-98-8 2-(4-Amino-phenyl)-propionyl chloride 
• 31842-01-0 indoprofen 
• 56353-52-7 2-(4'-amino-3'-nitro-phenyl)-propionic acid 
• 1606973-52-7 2-(4-(4-(3-chlorophenyl)-6-ethyl-1,3,5-triazin-2-ylamino)phenyl)propanoic acid 
• 1374573-46-2 2-[4-(1H-tetrazol-1-yl)phenyl]propanoic acid 
• 1391982-24-3 N-(4-(3-chlorophenyl)thiophen-2-yl)-2-(4-(ethylsulfonyl)phenyl)propanamide 
• 1391982-23-2 ethyl 2-(4-(ethylsulfonyl)phenyl)propanoate 
• 1391982-22-1 ethyl 2-(4-(ethylthio)phenyl)propanoate 
• 1363179-16-1 2-(4-(ethylsulfonyl)phenyl)propanoic acid 
• 959585-30-9 2-(quinolin-6-yl)propanoic Acid 
• 76816-30-3 2-(2-amino-benzothiazole-6-yl)-propionic acid 
• 71526-67-5 2-[p-(2-troponylamino)phenyl]propionic acid 

Relevant articles and documents

Novel propanamides as fatty acid amide hydrolase inhibitors

Fatty acid amide hydrolase (FAAH) has a key role in the control of the cannabinoid signaling, through the hydrolysis of the endocannabinoids anandamide and in some tissues 2-arachidonoylglycerol. FAAH inhibition represents a promising strategy to activate the cannabinoid system, since it does not result in the psychotropic and peripheral side effects characterizing the agonists of the cannabinoid receptors. Here we present the discovery of a novel class of profen derivatives, the N-(heteroaryl)-2-(4-((2-(trifluoromethyl)pyridin-4-yl)amino)phenyl)propanamides, as FAAH inhibitors. Enzymatic assays showed potencies toward FAAH ranging from nanomolar to micromolar range, and the most compounds lack activity toward the two isoforms of cyclooxygenase. Extensive structure-activity studies and the definition of the binding mode for the lead compound of the series are also presented. Kinetic assays in rat and mouse FAAH on selected compounds of the series demonstrated that slight modifications of the chemical structure could influence the binding mode and give rise to competitive (TPA1) or non-competitive (TPA14) inhibition modes.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kirl.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES

Psoralen compounds of Formula (I): wherein (N+ Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C1-C30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents; R1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl; n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.